R
Reapplix
An active approach to wound healing
About Reapplix
Reapplix is a pioneering company specializing in advanced wound care solutions, particularly for diabetic foot ulcers. The company operates in the healthcare and medical technology market, focusing on providing innovative therapies to improve patient outcomes. Reapplix's core product, the 3C Patch System, is a personalized wound healing solution that has shown significant efficacy in clinical trials and has been recommended by international medical groups. The 3C Patch System works by utilizing a patient's own blood to create a patch that promotes healing in chronic wounds, particularly diabetic foot ulcers, which are notoriously difficult to treat. Reapplix primarily serves healthcare providers, including hospitals and clinics, that treat patients with chronic wounds. The business model is based on selling the 3C Patch System to these healthcare providers, who then use it as part of their treatment protocols. Revenue is generated through the sale of the 3C Patch System kits and related services. The company has gained recognition through positive outcomes published in reputable medical journals and presentations at major scientific conferences.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Birkerød, Denmark
- Employees
- 42
- Open positions
- None listed
- Dealroom signal
- 48.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Nordic Rising Star 2022, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jul 2020 | $20M | $80M | MK Ventures Venture Capital · Lauxera Capital Partners · North-East Healthcare Investment | — |
| LATE VCEquity / VC | Oct 2019 | $3.7M | $15M | Seed Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Reapplix is 350 monthly website visits, down 83.3% over the last three months. Reapplix's team grew 13.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Accelerace
Series A2 investors entered at this stage
Seed Capital
Novo Ventures
Series B and later3 investors entered at this stage
- MCMK Ventures Venture Capital
Lauxera Capital Partners- NINorth-East Healthcare Investment
Other known investors4 additional known investors
Export and Investment Fund of Denmark
Market Maturation Fund
Novo Holdings
PSV
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reapplix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reapplix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.